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ciation for Thoracic Surgerydoi:10.1016/j.jtcvs.2004.05.023Objective: This study was undertaken to evaluate the efficacy of a new adjuvant
protocol with octreotide, alone or in combination with radiotherapy, in radically
resected large cell neuroendocrine carcinomas of the lung.
Methods: Between 1990 and 2001, a total of 18 consecutive patients affected by
large cell neuroendocrine carcinomas of the lung were operated on. Lobectomy and
systemic lymphadenectomy were performed in all cases. Postoperative radiotherapy
was performed when stage was higher than Ib. Ten patients with positive results of
preoperative indium In-111 pentetreotide scintigraphy received octreotide after the
operation.
Results: Nine patients (50%) had local recurrences or distant metastases (mean
recurrence time 14 months); palliative chemotherapy was given, but all patients
died. In 10 cases (55.5%) octreotide alone or in combination with radiotherapy was
administered as adjuvant treatment; 9 of these patients (90%) are alive and free of
disease (P  .0007), and the other had liver and brain metastases 21 months after
surgery.
Conclusions: Our preliminary results seem to demonstrate the efficacy of octreotide
as adjuvant therapy in large cell neuroendocrine carcinomas of the lung when results
of preoperative indium In-111 pentetreotide scintigraphy were positive. Further
study are required to assess the utility of octreotide in patients with negative results
of indium In-111 pentetreotide scintigraphy.
Large-cell neuroendocrine carcinoma (LCNC) of the lung representsabout 2% to 3% of lung malignancies and it is known for its poorprognosis.1,2 The recent Travis classification of neuroendocrine tu-mors of the lung3 recognizes four types of neuroendocrine tumors:typical and atypical carcinoid, respectively low- and intermediate-grade tumors, and LCNC and small cell lung carcinoma, high-grade
neuroendocrine malignancies. Histologic criteria3 to diagnose LCNC are as follows:
(1) a tumor with neuroendocrine morphologic appearance at light microscopy
(organelle nesting, palisading, rosettes, and trabeculae), (2) high mitotic rate (11
events/mm2), (3) the presence of necrosis (centrilobular or in form of large areas),
(4) the presence of large cell size, low nuclear to cytoplasmic ratio, vesicular
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TSchromatin, and frequent prominent nuclei, and (5) positive
immunohistochemical staining for one or more neuroendo-
crine markers (neuron-specific enolase [NSE], chromo-
granin A, synaptophysin).
LCNCs of the lung are characterized by early relapses
even in case of radical surgical resection. At this time it is
not clear how affected patients should be treated. Surgery is
considered the primary therapeutic option, usually followed
by radiotherapy in case of T3 or N1-2 disease. Chemother-
apy is proposed as palliative treatment when relapses are
diagnosed, but survival does not appear to be influenced by
this treatment. Somatostatin inhibits the secretion of a broad
range of hormones, including growth hormone, insulin,
glucagon, and gastrin. Octreotide is an 8–amino acid long-
acting somatostatin synthetic analog characterized by a re-
markable biologic stability, higher than that of somatostatin,
and biologic activities that overlap those of the native hor-
mone. Its antitumoral effects are obtained by the inhibitions
of neoplastic cell growth and angiogenesis, which have been
well demonstrated in vitro. Octreotide’s effects are medi-
ated by somatostatin receptor subtype (sst) 2 and 5 activa-
tion, which results in inhibition of adenyl cyclase, decreased
conductance of voltage-sensitive calcium channels, activa-
tion of potassium channels, and stimulation of tyrosine
phosphatase activity.4
Octreotide is effective in the management of acute man-
ifestations of the carcinoid syndrome. Octreotide is rou-
tinely used in neuroendocrine tumors of the gut, whereas at
present experience with lung neoplasms with neuroendo-
crine features remains limited. We report a clinicopatho-
logic study of 18 consecutive cases of radically resected
LCNC of the lung; in 10 of them octreotide was adminis-
tered alone or in combination with radiotherapy as adjuvant
treatment. The aim of this preliminary study was to evaluate
the effectiveness of this new adjuvant protocol in reducing
tumor recurrence, thus prolonging survival.
Material and Methods
Between 1990 and 2001, a total of 1580 patients underwent radical
resection of bronchogenic carcinoma at our department. Of these,
18 (1.2%) were operated on for LCNC. Surgical specimens were
all retrospectively reviewed by our pathologists, and diagnosis of
LCNC was achieved according to the 1999 criteria of Travis and
colleagues.3 Immunohistochemical stains included the general
neuroendocrine markers, with polyclonal antibodies to synapto-
physin (DAKO A/S, Glostrup, Denmark), chromogranin A (Roche
Diagnostics GmbH, Mannheim, Germany), and NSE (DAKO
A/S). For each antibody the percentage of positive cells (0 for
negative, 1 for 1%-25%, 2 for 26%-50%, 3 for 50%) and
the intensity of staining (0 for negative, 1 for weak, 2 for moderate,
and 3 for strong) were recorded. Immunohistologic neuroendo-
crine markers were considered positive if more than 10% of
neoplastic cells reacted with an intensity of 2 or greater. Three
other patients were excluded from this study because they were
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mous cell carcinoma).
There were 11 male (61%) and 7 female patients; mean age was
63 years (range 48-71 years). Patients’ clinical characteristics are
shown in Tables 1 and 2. At the time of presentation, 4 patients
(22.2%) were free of symptoms, with the tumor incidentally dis-
covered. In the other 14 cases, symptoms at presentation were as
follows: chest pain (n  5), hemoptysis (n  5), dyspnea (n  4),
weigh loss (n  3), and persistent cough (n  7). Thoracic
computed tomographic scan was performed in all cases; chest wall
invasion was evident in 2 patients (11.1%) and confirmed at
intervention and mediastinal lymph node enlargement in 1 (5.5%).
Transthoracic fine-needle aspiration biopsy was performed in 6
cases (33.3%). Diagnosis of non–small cell lung carcinoma
(NSCLC) was achieved in 5 cases (83.3%), the remaining biopsy
yielded inconclusive results. Bronchoscopy was performed in all
patients; the diagnosis of NSCLC was made in 5 (27.7%), and the
diagnosis of atypical bronchial carcinoid was made in 1 (5.5%).
Preoperative serum neoplastic markers (carcinoembryonic antigen,
tissue polypeptide antigen, NSE, chromogranin A) were recorded
when available. Because it was available in our hospital, indium
In-111 pentetreotide scintigraphy (OctreoScan; Mallinckrodt Inc,
Hazelwood, Mo) was routinely performed in the preoperative
assessment and follow-up of all patients with suspected or proven
neuroendocrine tumor of the chest. Ten patients (55.5%) were
submitted to OctreoScan because of high NSE and chromogranin
A serum levels (just because of the high probability of tumors with
neuroendocrine features) or preoperative diagnosis of neuroendo-
crine tumor. Preoperative OctreoScan showed pathologic uptake
corresponding to the tumor only.
Follow-up
All patients were directly followed up at our institution with
periodic outpatient clinics. Data regarding survival and presence,
type, and site of recurrence were recorded. No patients were
unavailable for follow-up.
Statistical Analysis
Survival analysis was performed with the Kaplan-Meier curve.
Differences between survival curves were computed with the log-
rank test. Statistical analysis were performed with STATISTICA
release 6 software (StatSoft Inc, Tulsa, Okla).
Results
All patients underwent radical tumor resection, and lobec-
tomy and systemic lymphadenectomy were performed in all
cases. In 2 cases en bloc chest wall resection was required.
One patient underwent mediastinoscopy, with histologic
diagnosis of lymph node metastasis of atypical carcinoid;
this patient underwent a left upper lobectomy with a defin-
itive histologic diagnosis of pT2 N2 LCNC.
We adopted the 1997 revised TNM system5 for classifi-
cation of LCNC. Median survival was 42 months. The 3-
and 5-year survivals were 63% and 35%, respectively (Fig-
ure 1).
Somatostatin receptors (sst2 and sst5) were detected by
polymerase chain reaction technique in all patients with
l 2005
Filosso et al General Thoracic Surgery
G
TSpositive results of preoperative OctreoScan, and results
were positive in all cases. Adjuvant therapy (radiotherapy)
was administered to all patients with a TNM pathologic
stage higher than Ib, according to our oncologists’ adjuvant
protocol. Postoperative radiotherapy (54 Gy in 2-Gy daily
fractions) was delivered with a 10-MeV linear accelerator
on the mediastinum (in case of N1 or N2 disease), chest wall
(in case of T3 tumors), or both. No adjuvant chemotherapy
was administered. In 10 patients (55.5%), those in whom
preoperative OctreoScan results were positive, adjuvant
medical therapy with long-acting octreotide formulation
(Sandostatina LAR 20 mg; Novartis Pharma, Milan, Italy)
at 20 mg every 28 days was administered alone (in patients
with stage Ib disease) or in combination with radiotherapy
(in patients with stage higher than Ib). Patients received
octreotide 1 month after surgery, and they are still continu-
ing this therapy. Nine of 10 patients (90%) are alive and do
not show tumor recurrence (P  .0007; Figure 2); the other
had tumor recurrences in the liver and in the brain 21
months after a left upper lobectomy for pT2 N2 LCNC, and
she survived 32 months after surgery. Octreotide was well
tolerated in all cases, with only pain at the site of injection,
transient nausea, abdominal cramps, and sometimes diar-
rhea recorded. No patients stopped the therapy. Follow-up
was planned with chest radiographs every 3 months and
thoracic, upper abdomen, and brain computed tomographic
TABLE 1. Clinical characteristics and patient outcomes
Age
(y) Sex Intervention TNM Site of recurrence
R
63 M RUL T2 N0 Mediastinum, liver
70 M LLL T2 N0 Brain
66 F LUL T2 N1 None
52 M LLL  ribs T3 N1 Liver
48 M RUL T2 N1 None
58 F RUL  ribs T3 N0 Chest wall
66 F LUL T2 N1 None
68 M LLL T2 N2 Adrenal
71 M RLL T2 N1 None
70 M RLL T2 N1 None
65 M LUL T2 N2 None
66 F RLL T2 N2 Brain
54 F RUL T2 N0 brain
58 M LUL T2 N1 Liver, adrenal
56 F LUL T2 N2 Liver, brain
67 M RLL T2 N0 None
59 M RUL T2 N1 None
62 M RLL T2 N0 None
All patients who are listed as dead died of their disease. RUL, Right upper
lobectomy.scan every 6 months. In recent years we have routinely used
The Journal of ThoraciOctreoScan and neoplastic serum markers (NSE and chro-
mogranin A) in all cases.
Tumor relapses occurred in 9 patients: 8 of these (88.8%)
had not received octreotide as adjuvant therapy. Mean re-
currence time was 19 months after surgery (range 9-41
months). OctreoScan was effective in detecting the recur-
rence sites in all patients. Palliative chemotherapy was
proposed for all patients with tumor recurrence; cisplatin (or
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14 19 5 Dead
50 Yes Alive
19 24 5 Dead
43 Yes Alive
27 38 11 Dead
61 Yes Alive
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31 42 11 Dead
10 18 8 Dead
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months (range 2-11 months).
Discussion
In the 1999 World Health Organization classification of
Figure 1. Over
Figure 2. Comparison of survival curves with and withlung tumors,3 LCNC and small cell neuroendocrine carci-
822 The Journal of Thoracic and Cardiovascular Surgery ● Aprinoma represent the high-grade entities among neuroendo-
crine neoplasms. The aggressive clinical behavior of LCNC
is underlined by its poor prognosis and its high frequency of
local or systemic recurrence after radical resection, even in
early stages.2,6-9 Dresler and colleagues2 reported that stage
urvival curve.
djuvant medical treatment with octreotide (P  .0007)I LCNC has an 18% 5-year survival, and Jiang and associ-
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nosis of LCNC relative to other NSCLCs. Our experience
confirms these data; nevertheless octreotide, alone or in
association with radiotherapy, was effective in prolonging
survival and reducing the risk of tumor recurrence relative
to radiotherapy alone.
The optimal therapeutic treatment for LCNC of the lung
is still debated. Surgery remains the first therapeutic choice,
but surgery alone is ineffective to prolong survival, and
there is little consensus about the most effective adjuvant
therapy. Postoperative chemotherapy (cisplatin-based for
4-6 courses) was firstly proposed by Dresler and col-
leagues,2 but even in stage I it did not improve survival. The
insensitivity to chemotherapy of LCNC was suggested by
Lai and associates in 1989.10 They examined multiple-drug
resistance gene (MDR1) expression in a variety of lung
cancers. This gene is frequently expressed in neoplasm that
are chemoresistant or that have acquired chemoresistence.
They observed that most MDR1 gene expression was in the
subgroup of lung cancers with neuroendocrine features. No
significant data are available about the effectiveness of
adjuvant chemotherapy in NSCLC,11 but Shepherd and
coworkers12 reported that adjuvant chemotherapy resulted
in prolonged survival for many patients with stage I small
cell lung carcinoma. Because of a part of the neuroendo-
crine spectrum of lung tumors, Iyoda and colleagues13 pro-
posed adjuvant chemotherapy (cisplatin, carboplatin, or cy-
clophosphamide based) for large cell carcinomas with
neuroendocrine features, and they concluded that this regi-
men might be effective in prolonging survival of patients
with early stage large cell carcinoma with neuroendocrine
features. However, adjuvant chemotherapy was not so ef-
fective in cases of advanced disease.
Postoperative radiotherapy is generally administered in
advanced stages. We routinely administer adjuvant radio-
therapy (54 Gy) for LCNC higher than stage I, according to
our oncologists’ protocol. Our preliminary study demon-
strated the efficacy of this new adjuvant protocol including
octreotide alone or in combination with radiotherapy: it
significantly reduced the risk of tumor recurrence and pro-
longed survival in patients with radically resected LCNC.
We used a long-acting octreotide formulation, which is well
tolerated and easily administered. Patients receiving oct-
reotide had positive results of preoperative OctreoScan;
because OctreoScan reveals tumors with expression of sst2
and sst5, this information can be used to guide the clinician
when choosing medical therapy with octreotide. The pres-
ence of these receptors (in vivo octreotide targets) was
demonstrated by polymerase chain reaction technique in
surgical specimens as well. Because of technical difficulties,
it was not possible to demonstrate the presence of sst2 and
sst5 somatostatin receptors in pathologic specimens from
The Journal of Thoracipatients in whom preoperative OctreoScan was not per-
formed.
Somatostatin analogs of the new generation (octreotide,
lanreotide) are the first-line drugs to achieve a good clinical
control of hormone-mediated symptoms of carcinoid tu-
mors. The antigrowth effect of octreotide has been demon-
strated in vitro,14,15 but its effects on human tumors remain
controversial. Somatostatin biologic effects are mediated
through five different receptor subtypes (sst1-sst5) that have
been cloned and characterized to date. Octreotide, the first
somatostatin analog introduced for clinical use, binds with
high affinity to sst2 and sst5 receptors, binds with moderate
affinity to sst3, and does not bind at all to sst1 and sst4.15
Among the five somatostatin receptors subtypes, sst1, sst2,
and sst5 have all been implicated in the mediation of the
antiproliferative effect of somatostatin in vitro.16 Recent
observations have demonstrated that octreotide inhibits the
growth and induces apoptosis in neuroblastoma cells that
express high-affinity somatostatin receptors.17 The identifi-
cation of high-affinity somatostatin receptors in peritumoral
veins has been described previously.18 There is evidence
that tumor angiogenesis, which originates from and depends
on peritumoral host vessels, is influenced negatively by
somatostatin and somatostatinlike factors.19,20 Thus the ef-
ficacy of somatostatin analogs in tumor growth control
could be explained with this biologic mechanism, although
further in vitro and in vivo studies are required to confirm
this hypothesis.
In 2002 we described the long-term survivals of 7 pa-
tients with metastatic (liver) atypical bronchial carcinoids
for which octreotide was the only medical therapy.21 Re-
duction of 60% in liver metastasis size was observed in 2
cases, complete resolution was observed in 1, and complete
disease clinical control was observed in all. These results
are similar to others reported in literature,22-25 but the latter
are related only to metastatic gastrointestinal neuroendo-
crine tumors. No other large series have been reported
regarding the efficacy of octreotide in neuroendocrine lung
neoplasms.
Only two other systemic treatments (chemotherapy and
interferon) have been demonstrated to have an antitumoral
activity in neuroendocrine tumors, and both are less toler-
ated than octreotide because of their important adverse
effects. Combination chemotherapy with 5-fluorouracil and
streptozotocin gives a response rate ranging from 16% to
30%, but this therapy presents important gastrointestinal
and renal toxicity, with a poor tolerability for the pa-
tient.26,27 Interferon seems to have an impact on tumoral
growth similar to that of somatostatin analogs, but it neces-
sitates three subcutaneous injections weekly and entails
many adverse effects.28
On the contrary, in our experience octreotide was really
well tolerated, with few adverse effects: transient dose-
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cramps and sometimes diarrhea), pain at the site of injec-
tion, and cholesterol gallstone (1% symptomatic) have been
observed in our experience. All patients tolerated octreotide,
and none of them stopped the treatment. We strongly be-
lieve in the effectiveness of this biologic drug, and to our
knowledge this is the first report of successful combined
adjuvant treatment in LCNC of the lung.
In conclusion, LCNC is a relatively uncommon high-
grade tumor of the lung, characterized by poor prognosis
and high rates of recurrences even in early stages. Surgery
alone is ineffective in prolonging survival, and an optimal
adjuvant therapy has still not been identified. This is the first
description of the effectiveness of octreotide, alone or in
combination with radiotherapy, as adjuvant treatment in
radically resected LCNC of the lung. According to our
preliminary results, and despite the limitations of this study
(small number of cases and retrospective design), we pro-
pose the routine use of this protocol as postoperative treat-
ment, even if surgery has been radical.
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